Form 4: OptimizeRx Director Gregory Wasson Receives Significant Restricted Stock Unit Grant

OptimizeRx Corp. Director Gregory D. Wasson was granted 9,868 restricted stock units, aligning his interests with shareholders and increasing his beneficial ownership to 57,183 shares.

Summary

• OptimizeRx Corp. (OPRX) Director Gregory D. Wasson acquired 9,868 shares of common stock through a grant of restricted stock units (RSUs) on June 11, 2025.
• The RSUs represent a contingent right to receive shares of OptimizeRx common stock.
• The grant was made at a price of $0 per unit, which is typical for RSU grants.
• Following this transaction, Mr. Wasson's direct beneficial ownership of OptimizeRx common stock increased to 57,183 shares.
• The restricted stock units are set to vest in full on the earlier of the first anniversary of the grant date or the date of the Company's next annual meeting of shareholders.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the RSU grant aligns director interests with shareholders and is a standard compensation practice, indicating stability in corporate governance. There are no negative operational or financial implications disclosed.

Positives

• The grant of restricted stock units to a director aligns management and board interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• An increase in beneficial ownership by a director can signal confidence in the company's future prospects.

Negatives

• The grant of restricted stock units, upon vesting, will result in a slight dilution of existing shareholder equity, although this is a common form of equity compensation.

Risks

• The value of the restricted stock units is contingent on the future market price of OptimizeRx common stock, meaning the actual value realized by the director could be lower than the current market value if the stock price declines.
• The vesting schedule ties the director's compensation to continued service, which could be a risk if the company's performance deteriorates before vesting occurs.

Future Outlook

The restricted stock units granted to Director Gregory D. Wasson are scheduled to vest in full on the earlier of the first anniversary of the grant date (June 11, 2026) or the date of the Company's next annual meeting of shareholders, indicating a future transfer of shares.

Industry Context

This Form 4 filing reflects a standard practice of equity compensation for directors in publicly traded companies, particularly in the healthcare technology or pharmaceutical services sector where OptimizeRx operates. Such grants are common mechanisms to align the interests of board members with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as a form of director compensation is a widely adopted practice across various industries, including healthcare technology, aligning with corporate governance best practices.
• Companies like Veeva Systems (VEEV) or IQVIA (IQV), which operate in related healthcare technology and data services, frequently utilize RSU grants for their executive and board compensation to incentivize long-term performance and retention.
• The vesting schedule, tied to either a one-year anniversary or the next annual meeting, is a common structure for director RSU grants, similar to practices observed at companies like Teladoc Health (TDOC) or GoodRx (GDRX) in the digital health space.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Gregory D. Wasson, a director of OptimizeRx Corp., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting of RSUs, but also increased alignment of director's interests with shareholder value.
• Employees: No direct impact mentioned, but standard equity compensation practices can influence overall company culture and compensation philosophy.
• Director (Gregory D. Wasson): Receives equity compensation tied to the company's future performance, incentivizing long-term commitment and strategic oversight.

Next Steps

• The restricted stock units will vest on the earlier of June 11, 2026, or the date of OptimizeRx's next annual meeting of shareholders, at which point the shares will be transferred to Mr. Wasson.

Key Dates

Keywords

OptimizeRx, OPRX, Form 4, SEC filing, insider transaction, restricted stock units, RSU grant, director compensation, beneficial ownership, equity compensation